4/7/2009

Millennium: The Takeda Oncology agreed to develop and commercialize antibody-drug conjugates with Seattle Genetics. The deal is part of Seattle Genetics' effort to generate nondilutive capital and "leverage our proprietary technology to enhance our product portfolio," an official with the biotech firm said.

Related Summaries